• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Is FTC Lawsuit Altering The Investment Case For Hims Stock (HIMS)?

    Simply Wall St·09/09/2026 11:23:19
    Listen to the news
    • Hims & Hers Health is facing a class action in the Northern District of California after the FTC sued over alleged sharing of sensitive health data and disputed billing and cancellation practices between August 2025 and July 2026.
    • The legal complaints focus on core operating claims around privacy, disclosure and timing of prescription charges. These issues go directly to customer trust and could affect how Hims & Hers Health structures its telehealth model.
    • With fresh FTC and class action allegations around data sharing and billing practices, we will assess how this reshapes Hims & Hers Health’s investment narrative.

    Broaden your options by scanning hand picked 82 resilient stocks with low risk scores that may offer different risk profiles to Hims & Hers Health while you weigh the impact of these legal headlines.

    Hims & Hers Health Investment Narrative Recap

    To own Hims & Hers Health, you need to believe its telehealth model can keep attracting recurring, multi condition users while controlling acquisition costs and regulatory overhead. The FTC lawsuit and related class action point straight at that thesis, because they focus on data handling and billing clarity. Outcomes here could influence how aggressively Hims & Hers Health can use advertising platforms, how it sequences charges around intake forms, and what it spends on compliance. The most important near term swing factor is whether user growth and retention hold up if marketing and operating practices change.

    The class action linked to the FTC complaint sits alongside Hims launching the Hims brand in Australia through the Pilot rebrand and Eucalyptus acquisition. That move broadens the reach of its personalised care platform and extends local care availability to 24/7 access, which can matter for subscription style engagement. International rollouts also add regulatory and reimbursement complexity on top of the US issues now in focus. Execution across new clinical pathways, combinations of care, and always on support will influence whether expanding into markets like Australia offsets higher legal, compliance, and marketing demands.

    Even so, there is a separate pressure point that could matter more than the lawsuits if ...

    Read the full Hims & Hers Health narrative to see the case behind these numbers.

    Hims & Hers Health's current analyst narrative points to revenues of US$4.6b and earnings of US$241.0 million by 2029, built on assumed yearly top line growth of 21.6% and an earnings move of roughly US$383.0 million from a loss of US$142.0 million today to that 2029 profit forecast.

    Hims & Hers Health's forecasts place fair value at $31.23 versus a $28.17 share price, an 11% upside to its current price that could narrow fast.

    NYSE:HIMS 1-Year Stock Price Chart
    NYSE:HIMS 1-Year Stock Price Chart

    Exploring Other Perspectives

    One alternate narrative for Hims & Hers Health focuses squarely on data privacy risk. The most cautious analysts were already baking in slower progress, with revenue expectations of about US$4.3b and earnings near US$218.1 million by 2029, before this lawsuit. That is a far more pessimistic path. It shows how sharply opinions can differ, so it is worth exploring several viewpoints as this legal story evolves.

    If you want to see how other investors are thinking about Hims & Hers Health, compare these headline forecasts with 18 other fair value estimates for Hims & Hers Health.

    Decide For Yourself

    Don't just follow the ticker. Dig into the data and build a conviction that's truly your own.

    Looking for more investment ideas beyond Hims & Hers Health?

    While you weigh the legal and growth story around Hims & Hers Health, it can help to line it up against other opportunities that fit different risk and income profiles using the Simply Wall St Screener.

    • If capital preservation sits high on your list, take a look at 82 resilient stocks with low risk scores, which may offer a calmer ride through market swings.
    • For investors hunting for value, compare Hims & Hers Health with 49 high quality undervalued stocks, which pair stronger fundamentals with prices that screen as potentially conservative.
    • If income is the priority, weigh this telehealth stock against 6 dividend fortresses, which focus on higher yield and steadier payout records.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.